162 related articles for article (PubMed ID: 16123210)
1. Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs.
Dukarm RC; Steinhorn RH; Russell JA; Lakshminrusimha S; Swartz D; Cummings JJ
J Appl Physiol (1985); 2005 Dec; 99(6):2331-6. PubMed ID: 16123210
[TBL] [Abstract][Full Text] [Related]
2. The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation.
Dukarm RC; Russell JA; Morin FC; Perry BJ; Steinhorn RH
Am J Respir Crit Care Med; 1999 Sep; 160(3):858-65. PubMed ID: 10471609
[TBL] [Abstract][Full Text] [Related]
3. E4021, a selective phosphodiesterase 5 inhibitor, potentiates the vasodilator effect of inhaled nitric oxide in isolated perfused rat lungs.
Ohnishi M; Oka M; Muramatsu M; Sato K; Kira S; Fukuchi Y
J Cardiovasc Pharmacol; 1999 Apr; 33(4):619-24. PubMed ID: 10218733
[TBL] [Abstract][Full Text] [Related]
4. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
[TBL] [Abstract][Full Text] [Related]
5. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR
J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats.
Cohen AH; Hanson K; Morris K; Fouty B; McMurty IF; Clarke W; Rodman DM
J Clin Invest; 1996 Jan; 97(1):172-9. PubMed ID: 8550830
[TBL] [Abstract][Full Text] [Related]
7. Type V phosphodiesterase inhibition modulates endogenous immunoreactivities of endothelin-1 and endothelial nitric oxide synthase in pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
Takahashi T; Kanda T; Sumino H; Inoue M; Sato K; Sakamaki T; Kobayashi I; Iwamoto A; Nagai R
Res Exp Med (Berl); 1998 Apr; 197(6):319-28. PubMed ID: 9638794
[TBL] [Abstract][Full Text] [Related]
8. Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs.
Adachi H; Nishino M
Jpn J Pharmacol; 1998 May; 77(1):99-102. PubMed ID: 9639065
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Vemulapalli S; Watkins RW; Chintala M; Davis H; Ahn HS; Fawzi A; Tulshian D; Chiu P; Chatterjee M; Lin CC; Sybertz EJ
J Cardiovasc Pharmacol; 1996 Dec; 28(6):862-9. PubMed ID: 8961086
[TBL] [Abstract][Full Text] [Related]
10. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.
Deruelle P; Grover TR; Storme L; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2005 Apr; 288(4):L727-33. PubMed ID: 15608146
[TBL] [Abstract][Full Text] [Related]
11. A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery.
Saeki T; Adachi H; Takase Y; Yoshitake S; Souda S; Saito I
J Pharmacol Exp Ther; 1995 Feb; 272(2):825-31. PubMed ID: 7853200
[TBL] [Abstract][Full Text] [Related]
12. NO and prostaglandin interactions during hemodynamic stress in the fetal ovine pulmonary circulation.
Zenge JP; Rairigh RL; Grover TR; Storme L; Parker TA; Kinsella JP; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2001 Nov; 281(5):L1157-63. PubMed ID: 11597907
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension.
Evgenov OV; Busch CJ; Evgenov NV; Liu R; Petersen B; Falkowski GE; Petho B; Vas A; Bloch KD; Zapol WM; Ichinose F
Am J Physiol Lung Cell Mol Physiol; 2006 Apr; 290(4):L723-L729. PubMed ID: 16284211
[TBL] [Abstract][Full Text] [Related]
14. Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia.
Downing JW; Ramasubramanian R; Johnson RF; Minzter BH; Paschall RL; Sundell HW; Engelhardt B; Lewis R
Med Hypotheses; 2004; 63(6):1057-64. PubMed ID: 15504576
[TBL] [Abstract][Full Text] [Related]
15. Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme.
D'Amours MR; Granovsky AE; Artemyev NO; Cote RH
Mol Pharmacol; 1999 Mar; 55(3):508-14. PubMed ID: 10051534
[TBL] [Abstract][Full Text] [Related]
16. Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension.
Steinhorn RH; Russell JA; Lakshminrusimha S; Gugino SF; Black SM; Fineman JR
Am J Physiol Heart Circ Physiol; 2001 Jan; 280(1):H311-7. PubMed ID: 11123246
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
Dukarm RC; Morin FC; Russell JA; Steinhorn RH
Pediatr Res; 1998 Dec; 44(6):831-7. PubMed ID: 9853914
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide decreases lung liquid production via guanosine 3',5'-cyclic monophosphate.
Cummings JJ; Wang H
Am J Physiol Lung Cell Mol Physiol; 2001 May; 280(5):L923-9. PubMed ID: 11290516
[TBL] [Abstract][Full Text] [Related]
19. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Hanson KA; Ziegler JW; Rybalkin SD; Miller JW; Abman SH; Clarke WR
Am J Physiol; 1998 Nov; 275(5):L931-41. PubMed ID: 9815111
[TBL] [Abstract][Full Text] [Related]
20. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide.
Thusu KG; Morin FC; Russell JA; Steinhorn RH
Am J Respir Crit Care Med; 1995 Nov; 152(5 Pt 1):1605-10. PubMed ID: 7582302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
